The clinical laboratory course of immunodiagnosis applies immunological theories and techniques to diagnose clinical diseases. Chemiluminescent immunoassay (CLIA) uses chemiluminescent agents as biomarkers, integrating the specificity of antigen-antibody binding and the generation of light signals in the testing process. It boasts the advantages of high sensitivity, rapidity, and high automation. BDH Group chemiluminescent products adopt direct chemiluminescent technology and are equipped with high-speed analytical instruments to meet the demand for high-throughput testing in clinical settings.